HDMA honors pharmaceutical manufacturers with DIANA awards
PEAPACK, N.J. The Healthcare Distribution Management Association recently awarded its Distribution Industry Awards For Notable Achievements in Healthcare. The association has been honoring manufacturers of pharmaceutical and consumer products for excellence in new product introductions, product promotions and their overall business practices with HDMA healthcare distributors for almost 50 years.
One of the winners, Greenstone Ltd., was awarded Best Overall Generic Pharmaceutical Products Manufacturer in the over $100 million-sales category. This is the second consecutive year the Pfizer subsidiary has won the award. The finalists in this category were Qualitest Pharmaceuticals and Watson Labs, a Watson Pharma subsidiary.
Adams Respiratory Therapeutics won the DIANA in the over-the-counter category for Best New Product Introduction/Promotion, for Children’s Mucinex. The company also took home a win for the Best Overall Consumer Products Manufacturer in the more than $10 million range. The two finalists were Novartis and Schering-Plough.
Other winners included:
- Johnson & Johnson — Best New Product Introduction/Promotion in the health and beauty care category, for K-Y Intrigue.
- Pfizer — Best New Product Introduction/Promotion in the branded pharmaceutical products category, for the smoking cessation drug Chantix.
- AstraZeneca — Best Overall Branded Pharmaceutical Products Manufacturer in the over $300 million sales category. Finalists in this category were Boehringer Ingelheim and Alcon Labs.
Winners with smaller sales to distributors—less than $100 million in most cases—were Cara, Dr. Reddy’s and Reliant, for the Overall, Generic and Branded categories, respectively. Finalists in these three categories included, respectively, Omron Healthcare, Upsher-Smith Labs and Novo Nordisk.
Judges in these categories looked for a number of criteria, including high product service levels, a product line and marketing plan that contributed to sales growth, and support of distributor promotional programs.
Orphan drug application process to ease in U.S., Europe
WASHINGTON & LONDON The Food and Drug Administration, European Commission and European Medicines Agency have decided to ease the application process for orphan drugs, drugs that are necessary but would be expensive and unprofitable to develop, in a move aimed at increasing the development of treatments for rare diseases, according to Reuters.
The agencies have adopted a common application, which would allow drug companies to apply to both regions at the same time with one application.
Rare diseases are defined as those affecting fewer than five in 10,000 people in the European Union and fewer than 200,000 people in the United States. About 30 million people in the European Union and about 25 million Americans suffer from more than 6,000 rare diseases.
India’s drug makers move beyond generics
NEW DELHI, India
India’s big pharmaceutical companies are moving from generic drug manufacturing to introducing their own originally researched drug molecules, which are expected to hit the market by 2010-11, according to published reports.
Among the companies involved in research and development of the new molecules are Ranbaxy, Glenmark and Dr. Reddy’s. Altogether about 10 to 12 companies have molecules under various stages of development.
Research and development investments now account for as much as 7 percent to 9 percent of sales. For example, Ranbaxy invested $80 million in research and development in 2006-07; this year that number has gone up to $100 million.
The key for these companies will be to partner with more experienced pharmaceutical manufacturers to help conduct more original research and development on new drugs.